We advocate more pharmaceutical products to be tested in clinical trials to meet relevant efficacy endpoints and deliver clinical value in different wound segments.
Mia Phillipson, Professor and co-founder of Ilya Pharma is sharing our growth story and future strategy at Uppsalaväxer in Almedalen-a political festival in Visby, Gotland.
Professor Mia Phillipson, co-founder of Ilya Pharma is giving the view of our immune system, the scientific advances as well as opening up for using and targeting the immune system in development of next-generation biologics to treat current unmet medical needs. In Swedish. https://play.acast.com/s/alltduvelatveta/198omimmunforsvaretmedmiaphillipson
Interview by Chris Smith, BBC Radio Cambridgeshire - Cutting-edge radio show that peers over the horizon at the science of tomorrow. Link : https://www.thenakedscientists.com/podcasts/naked-scientists-podcast/say-hello-tomorrows-tech 15:25 - Wound-healing bacteria The interview took place at the Hello Tomorrow Global Challenge event in Paris 15th of March where Ilya Pharma was selected Top 80 of companies in deep tech globally and also the winner of the wellbeing track, sponsored by Loreal.
Biopharma Reporter covers News & Analysis on Biopharmaceutical Manufacturing & Bioprocessing Tech.
Microbiome Times is reporting in the ERA of the microbiome.
Ilya Pharma and our innovative drug candidates was featured by BioCentury. We are very happy to be selected as an emerging company to keep track of!
”Time heals all wounds...... but wounds heal faster with Lactobacillus” is the title of a commentary to our preclinical results (Vågesjö et al. 2018 PNAS) published by the very prestigious journal Cell-Host and Microbe. The authors summarizes our demonstration of a feasible and translatable therapeutic approach acceleration of wound healing with topical application of CXCL12-producing Lactobacilli and applauds the approach and the first steps in the drug development program. Chronic non-healing wounds represent a significant clinical problem and cost the healthcare system $19 billion annually. Our developed drug candidate being an advanced therapeutic medicinal product, is in the article referred to as a ”promising technology for the unsolved problem of delayed cutaneous wound healing”.